DARE Dare Bioscience Inc.

1.68
0  0%
Previous Close 1.68
Open 1.7
Price To Book 2
Market Cap 19189230
Shares 11,422,161
Volume 176,202
Short Ratio
Av. Daily Volume 1,188,705

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated in 2019 with data due 4Q 2020.
Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD)
Phase 2 top-line data due 2H 2019.
Ovaprene
Contraception
Phase 3 trial to be initiated 2H 2019.
DARE-BV1
Bacterial Vaginosis
Phase 1 top-line data due 2H 2019.
DARE-HRT1
Hormone replacement therapy

Latest News

  1. Four Healthcare Stocks Heating Up On Monday
  2. Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study
  3. Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference
  4. Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA
  5. Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®
  6. Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference
  7. Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference
  8. Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference
  9. Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
  10. What Kind Of Investor Owns Most Of Daré Bioscience, Inc. (NASDAQ:DARE)?
  11. Edited Transcript of DARE earnings conference call or presentation 13-Nov-18 1:30pm GMT
  12. DARE: DARE Adds Late-Stage Bacterial Vaginosis Candidate To Ever-Expanding Women’s Health Pipeline
  13. New Healthcare Trends Pushing Stocks Higher On Thursday
  14. Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis
  15. DARE: Ovaprene PCT Continues. TS Content Validity Study, Thermographic Study Underway
  16. Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
  17. Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
  18. Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast
  19. Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.